Hospital-acquired infections are on the rise and are a substantial cause of clinical and financial burden for healthcare systems. While infection control plays a major role in curtailing the spread of outbreak organisms, it is not always successful. One organism of particular concern is Acinetobacter baumannii, due to both its persistence in the hospital setting and its ability to acquire antibiotic resistance. A. baumannii has emerged as a nosocomial pathogen that exhibits high levels of resistance to antibiotics, and remains resilient against traditional cleaning measures with resistance to Colistin increasingly reported. Given the magnitude and costs associated with hospital acquired infections, and the increase in multidrug-resistant organisms, it is worth re-evaluating our current approaches and looking for alternatives or adjuncts to traditional antibiotics therapies. The aims of this review are to look at how this organism is spread within the hospital setting, discuss current treatment modalities, and propose alternative methods of outbreak management.
Keywords: ABC, A.baumannii complex; AMP, Antimicrobial peptides; Acinetobacter baumannii; Antimicrobial peptide; Bacteriophage; CRAB, carbapenem-resistant A.baumannii; Colistin; EPIC, Extended Prevalence of Infection in Intensive Care study; EU/EEA, European Union (EU) and European Economic Area (EEA) countries; FMT, faecal microbiota transplantation; HPV, Hydrogen peroxide vapour; MDR-AB, Multidrug-resistant Acinetobacter baumannii; MDR-GNB, Multidrug-resistant Gram-negative bacteria; MIC, minimal inhibitory concentrations; Microbiome restoration; Multidrug-resistance; SOAP, Sepsis in European ICUs study; UVC, UV-C light; XDR, Extensively-drug resistant.
© 2020 The Authors.